

DAFTAR PUSTAKA

- Ahmad A, Pate I, Parimilakrishanan S, Mohata GP. (2013). The Role of Pharmacoeconomics in Current Indian Healthcare System. *J Res Pharm Pr*; 2(1):3-9
- Afdhal, A.F. (2011). *Farmakoekonomi: Pisau analisis terbaru dunia farmasi*. Jakarta: PT. Penebar Swadaya
- Bayo, J., et al. (2012). Chemotherapy-induced nausea and vomiting: Pathophysiology and therapeutic principles. *Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, 14(6), 413-22. doi:10.1007/s12094-0818-y.
- Curm .C.P, Lester .S.C, Coran .R. S. (2003). *The Breast, Basic Pathology*. Philadelphia: Elsevier; p.705-17
- De Boer-Dennert, M. *et al.* (1997) 'Patient Perceptions of The Side-Effects of Chemotherapy: The Influence of 5HT3 Antagonists', *British Journal of Cancer*, 76(8), pp. 1055–1061. doi: 10.1038/bjc.1997.507.
- Dipiro, et all (2009) *Pharmacotherapy Handbook*. seventh edition. New York: McGraw Hill Medical.
- Dipiro, et all (2015) *LPV control for flexible launcher*. Ninth Edition, *Pharmacotherapy Handbook*. Ninth Edit. New York: McGraw Hill Medical. doi: 10.2514/6.2010-8193.
- Eisenberg, P. *et al.* (2003) 'Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting with Palonosetron, a Pharmacologically Novel 5-HT 3 Results of a Phase III, Single-Dose Trial Versus Dolasetron. *American Cancer Society*, 98 (Cancer). doi: 10.1002/cncr.11817.

- Gilmore, J. *et al.* (2018) 'Recent Advances in Antiemetics : New Formulations of 5HT₃ -Receptor Antagonists', *Cancer Management and Research*, 10, pp. 1827–1857.
- Grunberg, S.M., et al. (2004). Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics. *Cancer*, 100(10), 2261-8. doi:10.1002/cncr.20230.
- Grunberg, S. M., et l. (2011). Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-sate of the art. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, 19(1), S43-7. doi:10.1007/s00520-010-1003x.
- Grunberg, S.M, & Ireland, A. (2005). Epidemiology of chemotherapy induced nausea and vomiting. *Advanced Studies in Nursing*, 3(1), 9-15.
- Herrstedt, J., et al. (2005). Acute emesis: Moderately emetogenic chemotherapy. *Supportive Care in Cancer: official Journal of the Multinational Association of Supportive Carein Cancer*, 13(2), 97-1003. doi:10.1007/s00520-004-0701-7.
- Hesketh, P. J. (2008) 'Chemotherapy-Induced Nausea and Vomiting', *New England Journal of Medicine*, 358(23), p. 2482. doi: 10.1056/NEJMra0706547.
- Honeycut, A.A, et al. (2016). Guide to analyzing the cost-effectiveness of community public health prevention approaches. available at: aspe.hhs.gov/health/reports/06/cphpa/report.pdf.
- International Agency for Research on Cancer (2019) 'Estimated Cancer Incidence, Mortality and Prevalence Worldwide In 2018', *World Health Organization*. Available at: <http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>.
- Jain, S. *et al.* (2018) 'ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderat. A randomized , open-label non-inferiority study to compare palonosetron and ondansetron for prevention of

acute chemotherapy-induced vomiting in; Supportive Care in Cancer, (July). doi: 10.1007/s00520-018-4158-5.

Jia, Yao, et al. (2013). Knowledge about Cervical Cancer and Barriers of Screening Program among Woman in Wufeng Country, a High-Incidence Region of Cervical Cancer in China. *Plos One*. Volume 8 (7): 2-8.

Jordan, S. & Schmoll (2017) 'Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations', *The Oncologist*, 12(January). doi: 10.1634/theoncologist.12-9-1143.

Juliawan, D. G.A. et al. (2015). Karakteristik Pasien Leukemia Mieloid Kronik Di Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2014-2015. *Universitas Undayana*.

Kementrian Kesehatan RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi*. Jakarta: Kemenkes RI

Kementrian Kesehatan RI (2015) *Info DATIN-Situasi Penyakit Kanker*, *Journal of Chemical Information and Modeling*. doi: 10.1017/CBO9781107415324.004.

Kementrian Kesehatan RI. (2016). *Pedoman Teknis Analisis Farmakoekonomi Di Fasilitas Kesehatan*. Jakarta: Kemenkes RI.

Lanfranchi A and Brind J, (2005). *Breast Cancer : Risk and Prevention*, The Edition, Pounghkeepsie, New York.

Lincoln, J & Wilensky. (2008). *Kanker payudara: Diagnosis dan solusinya*. Jakarta: Prestasi Pustakarya

Makhinova T, Rascati K. (2013). Pharmacoeconomics Education in US Colleges and Schools of Pharmacy. *Am J Pharm Educ*; 77(7):1-5

Mpherson, K., Steel, C. M. and Dixon, J. M. (2000) 'Breast Cancer — Epidemiology, Risk Factors, and Genetics Risk Factors for Breast Cancer', *BMJ Clinical*

Review, 321(September).

Mustian, K. M. (2008) 'Chemotherapy-Induced Nausea and Vomiting', *US Oncol*, 4, p. 1. doi: 10.1038/jid.2014.371.

Nasif, H. (2011) 'Efektifitas Antiemetik Pada Pasien Yang Menggunakan Sitostatika Pasca Bedah Pada Berbagai Jenis Kanker Di Rumah Sakit Umum Daerah Dr. Achmad Mochtar Bukittinggi', *Jurnal Sains Dan Teknologi Farmasi*, 16(2), pp. 121–127.

NCCN. (2018). *Breast Cancer*. Version 1.2018. National Comprehensive Cancer Network, Inc.

Nurmainah et al. (2017). Efektivitas Biaya Penggunaan Ampisilin dan Sefatoksim pada Pasien Anak Demam Tifoid. *Jurnal MKMI*. Vol 13 (2): 131-138

Parathoduvil, A. A., Sisupalan, A. and Rema, P. L. (2017) 'Comparison of Antiemetic Effectiveness of Palonosetron Versus Ondansetron in Patients on Cancer Chemotherapy : A Prospective Observational Study in South Indians', 11(5), pp. 10–14. doi: 10.7860/JCDR/2017/25129.9818.

Pradono, J. dan Sulistyowati N. (2014). Hubungan Antara Tingkat Pendidikan, Pengetahuan Tentang Kesehatan Lingkungan, Perilaku Hidup Sehat Dengan Status Kesehatan Studi Korelasi pada Penduduk Umur 10-24 Tahun di Jakarta Pusat (Correlation between Education Level, knowledge of Enviromenta). *Buletin Penelitian Sistem Kesehatan*. Volume 17 (1) : 89-95.

Ramli, H. M, Rainy Umbas, Sonar S Panigoro. 2003. *Deteksi Dini Kanker*, Edisi ke III. Jakarta : FKUI

Setiawan, D et al. (2017). *Farmakoekonomi Modeling*. Purwokerto: UMP Press

Shahnaz Desianti., K. L. (2018) 'Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia', *Farmaka*, 16, pp. 134–145.

- Sinaga, M. 2017. *Karakteristik Penderita Leukemia Yang Di Rawat Inap Di RSUP H. Adam Malik Medan Tahun 2014-2016*. Skripsi. Medan : Fakultas Kesehatan Masyarakat. Universitas Sumatra Utara.
- Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simodibrata, K. M.,Setiati S., 2006. *Buku Ajar Ilmu Penyakit Dalam*. Fakultas Kedokteran Universitas Indonesia : Jakarta Pusat, pp.853
- Thwaites, R. and Townsend, R. J. (1998) ‘Pharmacoeconomics in The New Millennium a Pharmaceutical Industry Perspective’, *PharmacoEconomics*, 13(2), pp. 175–180. doi: 10.2165/00019053-199813020-00002.
- Trask, L.S. (2011). *Pharmacotherapy: A pathophysiologic approach* (8th ed). Chapter 1 Pharmacoeconomics: principles, methods, and applications. NNew York: The McGraw-Hill Companies, Inc.
- Virginia, Nisha. 2013. *Analisis Efektivitas-Biaya Ondansetron Generik Berlogo Dan Bermerk Dagang Pada Pasien Kanker Payudara Dengan Kemoterapi Emetogenik Moderat Di RS Kanker Dharmais Periode 2012*. Skripsi. Jakarta Fakultas Farmasi. Universitas Indonesia.
- Warr, D. G., (2005). Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 23(12), 2822-30. doi:10.1200/JCO.2005.09.050.
- Yulianti (2016) ‘Faktor-Faktor Risiko Kanker Payudara (Studi Kasus Pada Rumah Sakit Ken Saras Semarang)’, *Jurnal Kesehatan Masyarakat*, 4. Available at: <http://ejournal-s1.undip.ac.id/index.php/jkm>.